You searched for Antibody candidate - Page 51 of 69

News and Trends 14 Jul 2022

Agomab bags $114 million in thriving regenerative medicine sector

…candidate also blocks ALK-5, but in this case, it’s designed to be inhaled for the treatment of the condition idiopathic pulmonary fibrosis. Meanwhile, Agomab is developing two antibody drugs at…

July 14, 2022 - 3 minutesmins - By Victor Kotsev

News and Trends 26 Aug 2022

Cholesterol targeting antibodies produced by Bio-Rad Laboratories

…and anti-drug antibody (ADA) assays for evolocumab and its biosimilars. Bio-Rad says that evolocumab is a monoclonal antibody used for the treatment of hyperlipidemia, or elevated levels of cholesterol and…

August 26, 2022 - 2 minutesmins - By Liza Laws

News and Trends 20 Jul 2023

Endometrial cancer drug receives breakthrough therapy designation in China

…sintilimab (a PD-1 antibody) for the treatment of patients with advanced endometrial cancer with pMMR tumors that have failed at least one line of platinum-based therapy. A study for potential…

July 20, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 6 May 2016

Biotech of the Week: Affibody and its Super antibodies from Scandinavia

…€5.3M Revenues (in 2015) CEO: David Bejker Mission: Affibody’s key platform is Affibody molecules, a novel class of antibody mimetics which due to their size surpass most monoclonal antibodies (mAbs)…

May 6, 2016 - 2 minutesmins - By Joachim Eeckhout

News and Trends 28 Nov 2022

Lyvgen and Bristol Myers Squibb commitment to transform cancer care

…for patients who cannot benefit from existing therapy worldwide.” Lyvgen clinical collaboration LVGN7409, a recombinant monoclonal antibody that targets CD40 for activation optimally in tumor microenvironment, which is a member…

November 28, 2022 - 3 minutesmins - By Liza Laws

More News! 17 Oct 2018

The EU Patent of the Best Selling Drug Has Expired, What Does it Mean for Biotech?

AbbVie’s Humira, a treatment for inflammatory disease and the world’s best-selling drug, is no longer patent-protected in the EU. Competitors are already taking advantage of it. Humira is an antibody…

October 17, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 26 Mar 2018

Attacking an Ancient Virus Slows Multiple Sclerosis in Phase II

GeNeuro has released Phase IIb data showing that its antibody can reduce brain damage in patients with multiple sclerosis by going after an unusual target: a virus that has been…

March 26, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 2 Sep 2021

AC Immune’s Mixed Phase II Results Buoy Alzheimer’s Research

…with targeting tau. Their anti-tau antibody semorinemab yielded both positive and negative results in a phase II trial in people with Alzheimer’s disease. According to one established measure of patient…

September 2, 2021 - 5 minutesmins - By Jonathan Smith

News and Trends 13 Jan 2016

UK Biotech starts 2016 by signing a (Massive?) Immuno-Oncology Deal with AbbVie

…antibodies to further enhance the potency, safety profile and cost efficiency of immuno-oncology treatments. Their modular Antibody technology platform introduces an antigen binding site into the constant region of an…

January 13, 2016 - 2 minutesmins - By Philip Hemme

Best in Biotech 22 Jan 2024

Eight newly approved drugs that could become blockbusters in 2024

…make it on the list, TALVEY is a humanized monoclonal antibody to target multiple myeloma. It has been granted accelerated approval by the FDA to those patients who have received…

January 22, 2024 - 9 minutesmins - By Roohi Mariam Peter

acute heart failure 4teen4 pharmaceuticals

More News! 5 Dec 2019

German Biotech Raises €7M Series A to Treat Acute Heart Failure

4TEEN4 Pharmaceuticals has raised a Series A round of €6.9M to fuel the development of a first-in-class antibody drug that could reduce mortality in acute heart failure. The round was…

December 5, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 18 Jun 2020

Belgian mRNA Vaccine for Covid-19 Receives €34M Series B Boost

…have some possible drawbacks. Antibody responses can decline quickly if not backed up by T helper cells, also known as ‘memory’ cells, and it’s possible that a weak antibody response…

June 18, 2020 - 3 minutesmins - By Helen Albert

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Search Results for: Antibody candidate

Agomab bags $114 million in thriving regenerative medicine sector

Cholesterol targeting antibodies produced by Bio-Rad Laboratories

Endometrial cancer drug receives breakthrough therapy designation in China

Biotech of the Week: Affibody and its Super antibodies from Scandinavia

Lyvgen and Bristol Myers Squibb commitment to transform cancer care

The EU Patent of the Best Selling Drug Has Expired, What Does it Mean for Biotech?

Attacking an Ancient Virus Slows Multiple Sclerosis in Phase II

AC Immune’s Mixed Phase II Results Buoy Alzheimer’s Research

UK Biotech starts 2016 by signing a (Massive?) Immuno-Oncology Deal with AbbVie

Eight newly approved drugs that could become blockbusters in 2024

German Biotech Raises €7M Series A to Treat Acute Heart Failure

Belgian mRNA Vaccine for Covid-19 Receives €34M Series B Boost

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!